Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425003 · ClinicalTrials.gov registry record · Phase 1
Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
A Phase 1 study, sponsored by Calico Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06425003 is a Phase 1 study that has completed, run by Calico Life Sciences. The registered enrollment target is 7 participants.
The verdict
NCT06425003, a Phase 1 study, has completed, sponsored by Calico Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.
Interventions
- DRUG [14C] ABBV-CLS-7262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425003
The ClinicalTrials.gov registry entry for NCT06425003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calico Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C] ABBV-CLS-7262 is the first listed.
NCT06425003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06425003 about?
NCT06425003 is a clinical study titled "Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration". The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.
What is the current status of trial NCT06425003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-05-21. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT06425003?
The interventions under investigation include: [14C] ABBV-CLS-7262 (DRUG).
Who is sponsoring clinical trial NCT06425003?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.